戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              dDAVP decreased phosphorylation of both JNK1/2 (T183/Y18
2                                              dDAVP induced gene expression of P2X(1), which localized
3                                              dDAVP treatment (10(-9) M, 24 h) on mpkCCDc11 cells sign
4                                              dDAVP, on the other hand, had no effect.
5  C-terminally truncated analogues of [Val(4)]dDAVP, 2, modified in positions 2, 3, and 7 and/or at th
6 ydration, treated with desmopressin acetate (dDAVP), or water loaded.
7 -3-3 interaction that was modulated by acute dDAVP treatment.
8 AZ-KD cells under basal conditions and after dDAVP treatment, respectively.
9 vels was observed in the outer medulla after dDAVP infusion.
10 with the type 2 vasopressin receptor agonist dDAVP increased mRNA and protein levels of AQP2 alongsid
11 ther forskolin or the V(2)-selective agonist dDAVP would increase apical membrane expression of UT-A1
12                 In contrast, the V2R agonist dDAVP significantly increased tumor growth.
13 rivation or administration of the VR agonist dDAVP did not increase urine osmolality of AC6-deficient
14   First, the vasopressin receptor-2 agonist, dDAVP, was delivered to the renal medulla resulting in a
15 g) in the presence of the vasopressin analog dDAVP (0.1 nM, 30 min) allowed quantification of 11,570
16         Rats received the vasopressin analog dDAVP by osmotic minipump plus either a daily water load
17  The V2 receptor-specific vasopressin analog dDAVP increased Ser(P)269-AQP2 abundance more than 10-fo
18 were then exposed to the vasopressin analog, dDAVP, to assess the role of these transcription factors
19 fusion of the antidiuretic hormone analogue, dDAVP, resulted in systemic hypotonicity in trpv4-/- mic
20                              Dehydration and dDAVP stimulated translocation of AQP-2 from intracellul
21 priately stimulated by water deprivation and dDAVP.
22                                Forskolin and dDAVP significantly increased UT-A1 abundance in the api
23 54 phosphopeptides decreased in abundance by dDAVP showed a predominance of so-called "proline-direct
24 ysis of the 273 phosphopeptides increased by dDAVP showed a predominance of so-called "basophilic" mo
25 nd AQP3 mRNA, and cAMP production induced by dDAVP (desmopressin).
26 nb, Stat3) were significantly upregulated by dDAVP in either control or TAZ-KD conditions.
27  divided into two groups: control (continued dDAVP) and water-loaded (continued dDAVP plus a daily or
28 continued dDAVP) and water-loaded (continued dDAVP plus a daily oral water load).
29 nce of the vasopressin analog, desmopressin (dDAVP).
30 nt responded to large doses of desmopressin (dDAVP) which decreased urine volume from 10 to 4 I/day.
31 labeling intensity in TAZ-KD cells following dDAVP stimulation.
32 rsed by water restriction reestablished high dDAVP-stimulated kidney levels of AQP-2 after 4 d of wat
33 wth factor (CCN2) increased significantly in dDAVP-treated Pkd1KO mouse kidneys, we examined its role
34 ggests its role as a TAZ-regulated target in dDAVP response pathway.
35                  Osmotic minipumps to infuse dDAVP, the V2-selective vasopressin agonist (5 ng/h) for
36       Furthermore, AC6-deficient mice lacked dDAVP-promoted inner medullary cAMP formation and phosph
37 re (SILAC) with two treatment groups (0.1 nM dDAVP or vehicle for 30 min), we carried out quantificat
38                            In the absence of dDAVP, P2Y(1) and P2Y(4) receptors localized to the apic
39          When clinically tested, infusion of dDAVP at variable doses produced a partial increase in t
40 ical membrane labeling of ROMK in the TAL of dDAVP-treated rats, as assessed by immunocytochemical an
41 t in polyuria and polydipsia with the use of dDAVP (1-desamino-8-D-arginine-vasopressin).
42     Importantly, YAP inactivation blocks the dDAVP-induced increase in myofibroblasts in Pkd1KO kidne
43            Accordingly, Nr4a1-KD reduced the dDAVP-induced upregulation of Aqp2 mRNA and protein.
44 wnregulation of AQP-2 expression compared to dDAVP-infused control rats was seen in the inner medulla
45                     Results were compared to dDAVP-infused rats fed solid chow.
46                      Basolateral exposure to dDAVP induced AQP2 localization to the apical membrane,
47 a decrease in phosphorylation in response to dDAVP in vivo.
48 s did not change in abundance in response to dDAVP.
49 hese proline-directed kinases in response to dDAVP.
50 ed NR4A1 protein levels in TAZ-KD cells upon dDAVP stimulation.
51                        V2R stimulation using dDAVP increased the renal interstitial myofibroblast pop
52 ist, or 1-desamino-8-D-arginine vasopressin (dDAVP, 5 ng), a V2 agonist.
53 ion of 1-deamino-(8-D-arginine)-vasopressin (dDAVP), a vasopressin V2 receptor-selective agonist, for
54 t with 1-deamino-[8-D-arginine]-vasopressin (dDAVP) by osmotic mini-pump, rats were divided into two
55 ups of 1-deamino-[8-D-arginine]-vasopressin (dDAVP)-infused rats were water-loaded; after establishme
56 pressin (desamino-d-arginine(8) vasopressin, dDAVP, 1) is a potent vasopressin 2 (V(2)) receptor (V(2
57 ts reduced cAMP and ERK1/2 activation, while dDAVP treatment had the reverse effect.
58                          Water loading (with dDAVP infusion) resulted in increased whole-kidney abund
59 reated Pkd1 gene knockout (Pkd1KO) mice with dDAVP, a V2R agonist, for 3 days and evaluated the effec